AUTL AUTL
Company Profile ↓Company Overview
AUTL (AUTL) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 566.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $75.39M (+644.9% YoY); net profit $-287.53M.
- Trailing 12 Months Year-on-year growth — revenue +644.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 566.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 566.32% |
| 1 Year: | 644.94% |
Stock Price Performance
| 1 Year: | -20.17% |
| 6 Months: | +37.68% |
| 3 Months: | +15.85% |
| 1 Month: | +18.01% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)67.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 566.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 0 | 0 | 8.98M | 20.92M | 21.19M | 26.22M |
| Operating Income | -36.19M | -39.06M | -37.35M | -39.15M | -44.38M | -42.91M | -38.76M | -58.93M | -67.88M | -65.24M | -61.22M | -71.62M | -59.51M |
| Net Income | -37.06M | -42.06M | -42.77M | -39.81M | -45.55M | -45.85M | -52.69M | -58.27M | -82.09M | -70.16M | -47.92M | -79.12M | -71.60M |
| Diluted EPS | -0.41 | -0.46 | -0.47 | -0.23 | -0.26 | -0.26 | -0.24 | -0.22 | -0.31 | -0.26 | -0.18 | -0.30 | -0.27 |
| R&D Expense | 28.36M | 30.79M | 31.48M | 27.39M | 33.23M | 32.32M | 30.67M | 36.61M | 40.32M | 26.73M | 27.43M | 27.89M | 21.21M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | - | 1.70M | 10.12M | 75.39M |
| Operating Income | -141.05M | -143.41M | -179.70M | -241.43M | -270.54M |
| Net Income | -142.10M | -148.84M | -208.38M | -220.66M | -287.53M |
| Diluted EPS | -1.97 | -1.57 | -1.20 | -0.86 | -1.08 |
| R&D Expense | 110.84M | 117.35M | 130.48M | 138.44M | 117.69M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 363.99M | 313.98M | 263.83M | 490.27M | 459.97M | 450.99M | 406.10M | 375.38M | 782.73M | 589.07M |
| Total Equity | 210.03M | 313.32M | 271.14M | 214.52M | 161.15M | 298.67M | 266.92M | 229.34M | 180.52M | 111.47M | 427.32M | 178.13M |
| Cash & Equivalents | - | 310.34M | 268.56M | 216.44M | 163.05M | 382.44M | 343.03M | 307.50M | 256.42M | 239.57M | 227.38M | 104.13M |
| Total Liabilities | - | - | 92.85M | 99.45M | 102.68M | 191.60M | 193.05M | 221.66M | 225.58M | 263.91M | 355.40M | 410.94M |
| Current Liabilities | - | - | 28.84M | 35.52M | 38.82M | 46.37M | 39.64M | 41.06M | 37.54M | 44.74M | 60.74M | 73.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -112.31M | -145.59M | -206.27M | -283.57M |
| Investing Cash Flow | - | -10.84M | -10.99M | -394.55M | 158.46M |
| Financing Cash Flow | - | 223.61M | -883.00K | 589.55M | -4.34M |
| Capital Expenditure | - | -10.84M | -10.99M | -34.82M | -27.13M |
| Free Cash Flow | - | -123.15M | -156.57M | -241.09M | -310.70M |
| Net Change in Cash | - | 100.46M | -157.46M | -11.27M | -129.45M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | -10,583.1% | -2,385.6% | -358.9% |
| Net Margin % | - | - | -12,272.3% | -2,180.5% | -381.4% |
| ROE % | -45.4% | -49.8% | -186.9% | -51.6% | -161.4% |
| ROCE % | - | -32.3% | -54.3% | -33.4% | -52.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AUTL
Autolus Therapeutics (AUTL) Stock Sees Split Analyst Revisions After Early Aucatyzl Launch Signals - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPNUVtYTVjNFUtLU9yZUdLSDMyc1V2X2R2amFlWkQ5VmNDQlhxSnBManN0emctU29oX1F0OGVwbnc4dl9acU94aXVNRUQ2TGVkMW9mR1NfNVNuTkNZUjRQNldYWmx3a3B0V0RQbGJZTUFySHRPV1Z3cGpXel9CWENXeW5VekJvdGNRVjl4c3…
Autolus Sets Aug. 11 Webcast for Q2 Results and Business Update - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQelRxNU9ZeUx4elI5SC1oS2F6VUc4VDJaeHlvQkNoemdVMVlFeWhIcldVMzVucnNNckJqWkhKaGtQbUthNS1xSTlTSVpfQWltVjYybk9wU2JWdnhYQTdtbHEySXVZX0c0SXVjT195NVRMRHJRaGhNSDVDU0xaeG9LV0RhbER5ekhvX1UtTE…
Autolus Therapeutics plc (AUTL) Stock Analysis: Exploring a 458.82% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPeG9aUUE4bHNIUW9lUmNMSjY4U3J6b0JONzJjbmhZUnRQUWV3aHc3Wmk4ZWVUcFNQaG9qUVNURFRndjF1cnp4bmVGWEZlYXRuSVBoMVVEQlNZR2lqTS0xMS1JcmoyRERlVEwzbnMwNXM3aU51MHFXQVBlUzZZZ1p2YVU0bU0yVEVvLUpFen…
Autolus Therapeutics: Navigating A Bumpy 2026 (NASDAQ:AUTL) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNSm9iQnI5anNhM0Nac2o3dW1TdnhZNW9OY1hZaEt1Y19LaFdyQmhXeFhsZ3pVcmNKUzN3bjZMcU9WTkhsT1hURm5Va214eU1FWnA0MmNFcmJUVGo1NVBVb1B6SmktR3JZcU55THR0Sjh6VnZYeWJOU24teG54TlRHT2pLVmNTZ0MzWUdzbU…
AUTL Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE8xT0M5eW96dUJfNjZnNllsclo4OUxSaFNnYjJnbFFMUWY0WC0wYU9XQV9saDBjdzBBZ3M0eEozRU5WNDlKZkJzc1VEejlMdXZUdG9pdmpoTEVueS1wZGNuSDFvRnA5VVNWZVRuX2hPT281VHBhX1VYa3VR?oc=5" target="_blank">AUT…
Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQS3FXaF9namloR05GMGFKRlFqa1pCZG5PLTBMSll6RTVLUlNhcTJvSmd3VmJ2Zy11REtfdmJsRVJobFU3TkNWNmREMEFVZjctazBId0JlRzk3RndtZ0lTaUlQT1J5ZHBqa2ZHaFExV3hDaVFOaUlpa0lWZVN1Mi0yMldYWm1CVm5oX0ZjZ0…
AUTL — Frequently Asked Questions
What is the current share price of AUTL?
As of 2026-08-05 17:25 PDT, AUTL trades at $1.90 on NASDAQ/NYSE. Its 52-week range is $1.21 to $2.47.
What is the P/E ratio of AUTL?
AUTL trades at a trailing price-to-earnings (P/E) ratio of -1.76.
Is AUTL a good stock to buy?
This page provides a data-driven analysis of AUTL, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.